2. From outbreak to bank

Several companies, including large pharma, came running to the call for a Zika vaccine. Purely philanthropic, you may think. Perhaps. But also for a slice of what could be a billion dollar pie. That’s right, it’s nearly unheard of for a vaccine against mosquito-borne viruses to hit blockbuster status, but according to Joseph Kim, CEO of Inovio, (who is leading the pack in developing a Zika vaccine) the potential to exceed $1B per year is there. And that’s the estimate with just US travelers. To paraphrase FDR, “The only thing we have to fear is fear itself. And not capturing the first mover advantage on a Zika vaccine.”